RA
OCUL icon

RoundAngle Advisors’s Ocular Therapeutix OCUL Stock Holding History

RoundAngle Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.41M Sell
166,484
-2,370
-1% -$22.6K 1.05% 40
2025
Q4 		$2.05M Sell
168,854
-7,946
-4% -$96.5K 1.49% 29
2025
Q3 		$2.07M Sell
176,800
-8,906
-5% -$106K 1.6% 28
2025
Q2 		$1.72M Sell
185,706
-10,169
-5% -$79.6K 1.44% 33
2025
Q1 		$1.44M Sell
195,875
-2,581
-1% -$19.8K 1.32% 34
2024
Q4 		$1.69M Buy
+198,456
New +$1.94M 1.61% 25

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RoundAngle Advisors's OCUL Position: Q1 2026 in Review

RoundAngle Advisors reduced its Ocular Therapeutix (OCUL) stake by 1.4% in Q1 2026, selling an estimated $22.6K and leaving 166,484 shares worth $1.41M. The position accounts for 1.05% of the portfolio, ranked #40.

RoundAngle Advisors first reported a position in OCUL in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.07M in Q3 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • RoundAngle Advisors held 166,484 shares of Ocular Therapeutix worth $1.41M as of Q1 2026.
  • RoundAngle Advisors sold 2,370 Ocular Therapeutix shares in Q1 2026, an estimated $22.6K.
  • Ocular Therapeutix made up 1.05% of RoundAngle Advisors's portfolio in Q1 2026, its #40 holding.
  • RoundAngle Advisors first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 6 quarters since.
  • RoundAngle Advisors's Ocular Therapeutix position peaked at $2.07M in Q3 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on RoundAngle Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.